UroGen Pharma Ltd

NASDAQ:URGN   3:59:53 PM EDT
16.71
+0.15 (+0.91%)
Earnings Announcements

Urogen Pharma Reports Q4 And FY20 Financial Results

Published: 03/18/2021 12:42 GMT
UroGen Pharma Ltd (URGN) - Urogen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments.
Q4 Loss per Share $1.38.
Anticipates 2021 Operating Expenses in the Range of $155 to $170 Million.
Revenue is expected to be $15.42 Million
Adjusted EPS is expected to be -$1.29

Next Quarter Revenue Guidance is expected to be $18.56 Million
Next Quarter EPS Guidance is expected to be -$1.29

More details on our Analysts Page.